InflaRx NV (FRA:IF0)
€ 1.35 0 (0%) Market Cap: 85.25 Mil Enterprise Value: 2.44 Mil PE Ratio: 0 PB Ratio: 0.89 GF Score: 32/100

InflaRx NV at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2022 / 04:15PM GMT
Release Date Price: €3.53 (-4.59%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Welcome, everyone, to the 40th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior analysts here at JPMorgan. I'm joined by Caleb Smith, Sumanth Kotha, [Malcolm Kuno], and Priyanka Grover from the team.

Our next presenting company is InflaRx, and presenting on behalf of the company, we have CEO Niels Riedemann. I want to remind the attendees that there is an app -- ask a question feature in the portal. And if anybody wants me to ask a question on their behalf, please put it in there. With that, Niels, take it away.

Niels C. Riedemann
InflaRx N.V. - Co-Founder, CEO & Executive Director

Thanks so much, Anupam. First of all, thanks so much for inviting us. We're honored to be part of this again, and looking forward to this presentation.

So I'll start right away. I just want to direct your attention to the forward-looking statements we're going to make. So please take note of the disclaimer.

Going forward to Page 3. So InflaRx

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot